PDF(630 KB)
PDF(630 KB)
PDF(630 KB)
HeLa细胞中INI1通过与E2A作用下调CD117
INI1 Down-regulates CD117 in HeLa by Interacting with E2A
目的:已经证明,CD117基因转录启始位点的上游-480bp包括4个E-box和一个GC-box。试验要确定INI1是否通过与E-box结合蛋白的相互作用来调控CD117。方法与结果:实验证明INI1过表达下调 CD117的mRNA水平和荧光素酶的活性,这个酶通过CD117启动子来启动。通过染色质共免疫沉淀反应实验,发现在HeLa细胞未损伤的染色质里面,INI1可以特定的结合CD117的启动子。绘制INI1在CD117启动子区域的结合位点图表明, E-boxes而不是GC-box对于下调CD117启动子的活性是必须的,这一点在Co-IP(共免疫沉淀)实验中被进一步的证实,在这个试验中INI1与E-box结合蛋白E2A在体内相互作用。结论:总的来说,INI1参与调节CD117的表达和细胞增殖。
Objective: It has been demonstrated that the -480 bp upstream of the CD117 gene transcriptional start site contains four E-boxes and one GC-box. It remains to be elucidated, however, whether INI1 regulates CD117 gene by interacting with E-box binding protein. Methods and Results: It is indicated that overexpression of INI1 down-regulates the CD117 mRNA level as well as a luciferase activity driven by CD117 promoter. Through ChIP assays, It shows that INI1 can specifically bind CD117 promoter within intact chromatin of Hela cells. Mapping of the INI1 binding site within the CD117 promoter region shows that the E-boxes but not the GC-box is necessary to down-regulate CD117 promoter activity, and this is further confirmed by a Co-IP experiment, in which INI1 functionally interacts with E-box binding protein E2A in vivo. Conclusion:Taken together, INI1 is involved in the regulation of CD117 expression and cell proliferation.
INI1 / CD117 / E2A / HeLa / 表达 {{custom_keyword}} /
INI1 / CD117 / E2A / Hela / Expression {{custom_keyword}} /
[1] Cetin N, Dienel G, Gokden M. CD117 expression in glial tumors. J Neurooncol, 2005, 75(2):195-202.
[2] Luo L, Zeng J, Liang B, et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol, 2011,91(2):596-602.
[3] Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci, 2004, 61(23): 2924-2931.
[4] Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer, 2008, 99(12):2065-2069.
[5] Smalley K S, Sondak V K, Weber J S. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol, 2009, 2(5): 643-650.
[6] Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene, 2007,401(1-2):38-45.
[7] Vandenbark G R, Chen Y, Friday E, et al. Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements. Cell Growth Differ, 1996, 7(10):1383-1392.
[8] Hassan H T. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res, 2009, 33(1): 5-10.
[9] Spinello I, Quaranta M T, Pasquini L, et al. PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis. Oncogene, 2009, 28(23): 2276-2288.
[10] Lécuyer E, Herblot S, Saint-Denis M, et al. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood, 2002, 100(7):2430-2440.
[11] Vitelli L, Condorelli G, Lulli V. A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts. Mol Cell Biol, 2000, 20(14):5330-5542.
[12] Pfister S M, Korshunov A, Kool M, et al. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol, 2010, 120(5):553-566.
[13] Isakoff M S, Sansam C G, Tamayo P, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA, 2005, 102(49): 17745-17750.
[14] Stojanova A, Penn L Z, The role of INI1/hSNF5 in gene regulation and cancer. Biochem Cell Biol, 2009, 87(1): 163-177.
[15] Parissi V, Caumont A, de Soultrait V R, et al. Inactivation of the SNF5 transcription factor gene abolishes the lethal phenotype induced by the expression of HIV-1 integrase in yeast. Gene, 2010, 247(1-2): 129-136.
[16] Maroun M, Delelis O, Coadou G, et al. Inhibition of early steps of HIV-1 replication by SNF5/Ini1. J Biol Chem, 2006, 281(32): 22736-22743.
[17] Wu D Y, Kalpana G V, Goff S P, et al. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol, 1996, 70(9): 6020-6028.
[18] Cheng S W, Davies K P, Yung E, et al. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet, 1999, 22(1): 102-105.
[19] Lee D, Sohn H, Kalpana G V, et al. Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA. Nature, 1999, 399(6735): 487-491.
[20] DelBove J, Kuwahara Y, Mora-Blanco E L, et al. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice. Mol Carcinog, 2009, 48(12): 1139-1148.
[21] Yamamoto H, Kohashi K, Tsuneyoshi M, et al. Heterozygosity Loss at 22q and Lack of INI1 Gene Mutation in Gastrointestinal Stromal Tumor. Pathobiology, 2011, 78(3):132-139.
[22] Han C, Liu H, Liu J, et al. Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex. Nucleic Acids Res, 2005, 33(20): 6555-6565.
[23] Zhang Z K, Davies K P, Allen J, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol, 2002, 22(16): 5975-5988.
[24] Bochar D A, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 2000, 102(2): 257-265.
[25] Slattery C, Ryan M P, McMorrow T. E2A proteins: regulators of cell phenotype in normal physiology and disease. Int J Biochem Cell Biol, 2008, 40(8): 1431-1436.
[26] Sobrado V R, Moreno-Bueno G, Cubillo E, et al. The class I bHLH factors E2-2A and E2-2B regulate EMT. J Cell Sci, 2009, 122(7): 1014-1024.
[27] Kondi-Pafiti A, Arkadopoulos N, Gennatas C, et al. Expression of c-kit in common benign and malignant breast lesions. Tumori, 2010, 96(6):978-984.
/
| 〈 |
|
〉 |
